Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J&J Posts More Promising Late-Stage Data for Psoriasis Drug

By Ryan Bushey | March 6, 2017

Johnson & Johnson (J&J) released more positive data regarding its potential blockbuster psoriasis treatment guselkumab.

The company reported results from two Phase 3 studies called VOYAGE 2 and NAVIGATE respectively.

Both investigations involved individuals with moderate-to-severe plaque psoriasis, but VOYAGE 2 focused on continued testing of guselkumab against rival therapy Humira whereas NAVIGATE evaluated guselkumab’s impact on patients who had an inadequate response after undergoing treatment with Stelara.

Guselkumab yielded a strong efficacy and safety profile compared to placebo and Humira, according to findings from the VOYAGE 2 analysis.

About 84 percent of patients taking J&J’s drug experienced significant improvements in complete or near complete skin clearance versus 67 percent taking Humira and 8.5 percent receiving the placebo.

A small percentage of patients in each group reported serious adverse side effects, but the percentage was higher in the group taking Humira.

Furthermore, the goal of the NAVIGATE trial was to test guselkumab’s treatment capabilities on patients who continued to suffer from mild to severe skin symptoms after 16 weeks of taking Stelara.

Outcomes from this particular study illustrated a consistent improvement for psoriasis patients taking guselkumab between weeks 28 and 40 during the study whereas individuals continuing to take Stelara attended twice as many office visits as their counterparts in the other arm of the trial.

Next steps for the company will entail gathering more data with extension studies aimed at assessing guselkumab’s long term efficacy, reported Endpoints News.

Detailed information regarding these trials will be presented at the annual Academy of Dermatology Meeting in Orlando, Florida over the weekend.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE